| 1 | experimental | 20,156 |
| 2 | active-treatment | 65 |
| 3 | attention-control | 59 |
| 4 | pro-self | 35 |
| 5 | se-deficient | 28 |
| 6 | early-start | 22 |
| 7 | exercise-only | 21 |
| 8 | ologen | 21 |
| 9 | breakout | 18 |
| 10 | non-purged | 16 |
| 11 | peg-only | 15 |
| 12 | cnep | 13 |
| 13 | balint | 12 |
| 14 | simvastatin-ezetimibe | 12 |
| 15 | almi | 11 |
| 16 | non-tzd | 11 |
| 17 | insulin-sensitization | 10 |
| 18 | no-choice | 10 |
| 19 | noninjection | 10 |
| 20 | teleophthalmologic | 10 |
| 21 | undrained | 10 |
| 22 | 1,600/800-mg | 9 |
| 23 | 80-day | 9 |
| 24 | acupuncture-rehabilitation | 9 |
| 25 | arginine-supplemented | 9 |
| 26 | insulin-provision | 9 |
| 27 | no-incentive | 9 |
| 28 | on-stimulation | 9 |
| 29 | acupuncture-medication | 8 |
| 30 | ilbt | 8 |
| 31 | immediate-start | 8 |
| 32 | insulin-increasing | 8 |
| 33 | intensive-treatment | 8 |
| 34 | itsi | 8 |
| 35 | low-score | 8 |
| 36 | nipc | 8 |
| 37 | non-hrt | 8 |
| 38 | nonextended | 8 |
| 39 | pirazolac | 8 |
| 40 | post-ep | 8 |
| 41 | ridge-preservation | 8 |
| 42 | rose-k | 8 |
| 43 | unexpanded | 8 |
| 44 | 1-st | 7 |
| 45 | a+-icd | 7 |
| 46 | all-on-4 | 7 |
| 47 | assistant-push | 7 |
| 48 | cha-cha | 7 |
| 49 | esfet | 7 |
| 50 | evening-dose | 7 |
| 51 | fittslog | 7 |
| 52 | high-nutrient | 7 |
| 53 | higher-calorie | 7 |
| 54 | ip-ssa | 7 |
| 55 | memoral | 7 |
| 56 | mr-fv | 7 |
| 57 | nasal-18 | 7 |
| 58 | neusidl | 7 |
| 59 | no-lymphadenectomy | 7 |
| 60 | octreotide-lar | 7 |
| 61 | pka-bis | 7 |
| 62 | rt-only | 7 |
| 63 | top/nic | 7 |
| 64 | vnr/cddp | 7 |
| 65 | 400/400-mg | 6 |
| 66 | acga | 6 |
| 67 | box-trained | 6 |
| 68 | cab-za | 6 |
| 69 | drmpa200z | 6 |
| 70 | early-discharge | 6 |
| 71 | egcg-treated | 6 |
| 72 | gole | 6 |
| 73 | high-variability | 6 |
| 74 | hip-as | 6 |
| 75 | ic+ccrt | 6 |
| 76 | immediate-treatment | 6 |
| 77 | inf-mtx | 6 |
| 78 | lwt | 6 |
| 79 | meric | 6 |
| 80 | non-p | 6 |
| 81 | non-po | 6 |
| 82 | open-enrollment | 6 |
| 83 | partin | 6 |
| 84 | physician's-choice | 6 |
| 85 | sodar | 6 |
| 86 | soht | 6 |
| 87 | steroid-maintenance | 6 |
| 88 | tj114-treated | 6 |
| 89 | 1-g/d | 5 |
| 90 | 1800-mg | 5 |
| 91 | 5-set | 5 |
| 92 | acprt | 5 |
| 93 | adult-learning | 5 |
| 94 | aerobic-training | 5 |
| 95 | capio | 5 |
| 96 | ceramic-polyethylene | 5 |
| 97 | dose-increase | 5 |
| 98 | ea-pa | 5 |
| 99 | enhanced-support | 5 |
| 100 | flu-only | 5 |
| 101 | heliox® | 5 |
| 102 | high-biomarker | 5 |
| 103 | high-h2 | 5 |
| 104 | ic+rt | 5 |
| 105 | ivb+trp | 5 |
| 106 | jian‑pi‑treated | 5 |
| 107 | low-variability | 5 |
| 108 | lumacaftor-ivacaftor | 5 |
| 109 | mpa100z | 5 |
| 110 | no-breakfast | 5 |
| 111 | non-bevacizumab | 5 |
| 112 | non-probiotics | 5 |
| 113 | non-video | 5 |
| 114 | nonshunt | 5 |
| 115 | nsaid-muscovite | 5 |
| 116 | ophthalmologist-based | 5 |
| 117 | se-supplemented | 5 |
| 118 | show-me-synch | 5 |
| 119 | txa-treated | 5 |
| 120 | usual-treatment | 5 |
| 121 | +avn-abl | 4 |
| 122 | 3-rd | 4 |
| 123 | abstinence-plus-condom | 4 |
| 124 | acupoint-shallow-puncturing | 4 |
| 125 | acupuncture-moxibustion-medication | 4 |
| 126 | acwl | 4 |
| 127 | alternating-sequence | 4 |
| 128 | amsa-guided | 4 |
| 129 | arterivirus | 4 |
| 130 | asdas-high | 4 |
| 131 | assess/advise/treat | 4 |
| 132 | bevacizumab-throughout | 4 |
| 133 | bf+ssc | 4 |
| 134 | classroom-centered | 4 |
| 135 | d5w-la | 4 |
| 136 | dexketoprophen | 4 |
| 137 | dopamine/dobutamine | 4 |
| 138 | drug-only | 4 |
| 139 | eth-oxy-carbonyl | 4 |
| 140 | exercise-intervention | 4 |
| 141 | free-viewing | 4 |
| 142 | fructose-supplemented | 4 |
| 143 | gemp | 4 |
| 144 | high-rope | 4 |
| 145 | higher-target | 4 |
| 146 | hyperoxia-preconditioned | 4 |
| 147 | i3c-treated | 4 |
| 148 | implementation-intention | 4 |
| 149 | ld+deb | 4 |
| 150 | li+ris/valproate | 4 |
| 151 | lidar | 4 |
| 152 | n-bppv | 4 |
| 153 | no-counting | 4 |
| 154 | no-heparin | 4 |
| 155 | non-counselling | 4 |
| 156 | non-navigation | 4 |
| 157 | non-saard | 4 |
| 158 | nonincentive | 4 |
| 159 | nonprophylactic | 4 |
| 160 | nttrap | 4 |
| 161 | o-acetyl | 4 |
| 162 | peer-assessment | 4 |
| 163 | phytosterol-containing | 4 |
| 164 | plc-cbt | 4 |
| 165 | ragb-treated | 4 |
| 166 | rapid-test | 4 |
| 167 | rotation/oscillation | 4 |
| 168 | skills-training | 4 |
| 169 | t12pr | 4 |
| 170 | tpn-soy | 4 |
| 171 | 3-np+krg | 3 |
| 172 | active-supplementing | 3 |
| 173 | acupuncture-massage | 3 |
| 174 | air-staging | 3 |
| 175 | ambient-acclimated | 3 |
| 176 | arts-based | 3 |
| 177 | at/imt | 3 |
| 178 | at/sham | 3 |
| 179 | banerji | 3 |
| 180 | break-out | 3 |
| 181 | cav2-cpi2 | 3 |
| 182 | cd+n-3pufas | 3 |
| 183 | cobraplus | 3 |
| 184 | combined-dose | 3 |
| 185 | comparison-group | 3 |
| 186 | dad-treated | 3 |
| 187 | dkc-50 | 3 |
| 188 | dobutamine-treated | 3 |
| 189 | dual-night | 3 |
| 190 | emf-exposed | 3 |
| 191 | expectancy-enhancing | 3 |
| 192 | febuxostat-treated | 3 |
| 193 | feno-guided | 3 |
| 194 | fmud+am | 3 |
| 195 | free-agent | 3 |
| 196 | frpp-treated | 3 |
| 197 | ge-tpn | 3 |
| 198 | id-vaccine | 3 |
| 199 | insulin-metformin | 3 |
| 200 | lateral-pin | 3 |
| 201 | mcpt4-deficient | 3 |
| 202 | midazolam-treated | 3 |
| 203 | mtf+nac | 3 |
| 204 | nhl-type | 3 |
| 205 | no-mouthpiece | 3 |
| 206 | no-sequence | 3 |
| 207 | non-breathing | 3 |
| 208 | non-colitis | 3 |
| 209 | non-glazed | 3 |
| 210 | non-tbhq | 3 |
| 211 | non-walking | 3 |
| 212 | nonpurpuric | 3 |
| 213 | o-carboxylate | 3 |
| 214 | one-vegetable | 3 |
| 215 | oxazolone-induced | 3 |
| 216 | oxcar | 3 |
| 217 | package-atmosphere | 3 |
| 218 | picture-associated | 3 |
| 219 | porocoat | 3 |
| 220 | pre-agent | 3 |
| 221 | rhg-csf-priming | 3 |
| 222 | rme/tpa/ec | 3 |
| 223 | rt-alone | 3 |
| 224 | sham-acupressure | 3 |
| 225 | thermal-treated | 3 |
| 226 | thermotolerance-inducing | 3 |
| 227 | tolterodine-treated | 3 |
| 228 | uroacitides+np | 3 |
| 229 | variable-attender | 3 |
| 230 | wide-open | 3 |
| 231 | α1-3 | 3 |
| 232 | 'exposed | 2 |
| 233 | 1.25-mg/ml | 2 |
| 234 | 10,000-lux | 2 |
| 235 | 4-night | 2 |
| 236 | 6.0-mg/d | 2 |
| 237 | abamectin/derquantel | 2 |
| 238 | actg5202 | 2 |
| 239 | active-active | 2 |
| 240 | ad/ttr+/+ | 2 |
| 241 | agre | 2 |
| 242 | agsb-repressed | 2 |
| 243 | albumin-treated | 2 |
| 244 | all-cellulose | 2 |
| 245 | alteplase-treated | 2 |
| 246 | anti-muscarinic-alone | 2 |
| 247 | ascorbate-deficient | 2 |
| 248 | before-freezing | 2 |
| 249 | bicavo-bipulmonary | 2 |
| 250 | cgprgps | 2 |
| 251 | change.the | 2 |
| 252 | conduit+nt-3+nscs | 2 |
| 253 | dbcare® | 2 |
| 254 | degarelix-ef | 2 |
| 255 | degraded-speech | 2 |
| 256 | diet+idet | 2 |
| 257 | diet-type | 2 |
| 258 | eae-mcherry | 2 |
| 259 | early-fit | 2 |
| 260 | eight-subject | 2 |
| 261 | es-treated | 2 |
| 262 | exercise-nmes | 2 |
| 263 | faster-paced | 2 |
| 264 | fda-required | 2 |
| 265 | firocoxib-treated | 2 |
| 266 | fit-only | 2 |
| 267 | high-upa/pai-1 | 2 |
| 268 | hipfit | 2 |
| 269 | homeotherm | 2 |
| 270 | hupa‑treated | 2 |
| 271 | immersion-time | 2 |
| 272 | infarct/no-training | 2 |
| 273 | infarct/training | 2 |
| 274 | instruction-only | 2 |
| 275 | intra-polymerase | 2 |
| 276 | isaac-ii | 2 |
| 277 | low-protein-diet | 2 |
| 278 | magnesium-supplemented | 2 |
| 279 | mcfa-supplemented | 2 |
| 280 | meso-phenyl | 2 |
| 281 | mg-sufficient | 2 |
| 282 | middling-onset | 2 |
| 283 | migraines/headache | 2 |
| 284 | mlpii-treated | 2 |
| 285 | morning-type | 2 |
| 286 | muscomorph | 2 |
| 287 | nbo6 | 2 |
| 288 | no-bicarbonate | 2 |
| 289 | no-cue | 2 |
| 290 | norepinephine | 2 |
| 291 | ortho-dihydroxyl | 2 |
| 292 | os-extended | 2 |
| 293 | ovariectomized-hysterectomized | 2 |
| 294 | placebo-minus | 2 |
| 295 | pleasant-neutral | 2 |
| 296 | polemical | 2 |
| 297 | rapid-advancement | 2 |
| 298 | resistance-load | 2 |
| 299 | saf100 | 2 |
| 300 | salt/tetracycline | 2 |
| 301 | second-cohort | 2 |
| 302 | single-consent | 2 |
| 303 | single-cutoff | 2 |
| 304 | sling-constraint | 2 |
| 305 | spleen-asthenia | 2 |
| 306 | stratified-randomized | 2 |
| 307 | tdf+emtricitabine | 2 |
| 308 | tourniquet-up | 2 |
| 309 | traditional-approach | 2 |
| 310 | training-plus-screening | 2 |
| 311 | us+mb-treated | 2 |
| 312 | 'close-out | 1 |
| 313 | 'existential | 1 |
| 314 | -acupuncture | 1 |
| 315 | 2-acyl | 1 |
| 316 | 6-hydroxydopamine-lesion | 1 |
| 317 | a-b-a-c-a-bc-a | 1 |
| 318 | access-only | 1 |
| 319 | across-intervention | 1 |
| 320 | adherence-counseling | 1 |
| 321 | after-implementation | 1 |
| 322 | alcohol-type | 1 |
| 323 | alternatives.the | 1 |
| 324 | anger-prime | 1 |
| 325 | ankle-brace | 1 |
| 326 | anti-sanitary | 1 |
| 327 | ap-training | 1 |
| 328 | aplocheiloid | 1 |
| 329 | ar-trained | 1 |
| 330 | arenesulfinyl | 1 |
| 331 | articaine-fentanyl | 1 |
| 332 | aspca | 1 |
| 333 | attentionally-constrained | 1 |
| 334 | balanced-placebo | 1 |
| 335 | bv-supplemented | 1 |
| 336 | chronically-instrumented | 1 |
| 337 | clinical/statistical | 1 |
| 338 | cobi/ftc/tdf | 1 |
| 339 | collision-free | 1 |
| 340 | comparisons.combined | 1 |
| 341 | cough-assisted | 1 |
| 342 | cows/dose | 1 |
| 343 | cyper | 1 |
| 344 | deep-diving | 1 |
| 345 | diet-treatment | 1 |
| 346 | diphtheria.our | 1 |
| 347 | dose-prediction | 1 |
| 348 | early-interventional | 1 |
| 349 | emotion-induction | 1 |
| 350 | endophenotype-based | 1 |
| 351 | endpoint-driven | 1 |
| 352 | equivalence/crossover | 1 |
| 353 | ethanol-injury | 1 |
| 354 | ethnospecific | 1 |
| 355 | ethoxycarbonyloxyethyl | 1 |
| 356 | eutocia | 1 |
| 357 | event-sampling | 1 |
| 358 | experimental-comparison | 1 |
| 359 | film-treated | 1 |
| 360 | fio2-guided | 1 |
| 361 | fluoxetine-containing | 1 |
| 362 | glucose-placebo | 1 |
| 363 | heated-patch | 1 |
| 364 | hiv-intervention | 1 |
| 365 | hypertrophy-intensity | 1 |
| 366 | ics-exposed | 1 |
| 367 | ilc+c-turp | 1 |
| 368 | ill-explained | 1 |
| 369 | immunized/vehicle | 1 |
| 370 | importantclinical | 1 |
| 371 | inaddition | 1 |
| 372 | incomplete-double | 1 |
| 373 | instructor-encouraged | 1 |
| 374 | intent-to-train | 1 |
| 375 | intentional-based | 1 |
| 376 | inter-trialist | 1 |
| 377 | intra-erspc | 1 |
| 378 | irs-v | 1 |
| 379 | ivpca-cryo | 1 |
| 380 | laboratory/microbiological | 1 |
| 381 | lai-dose | 1 |
| 382 | language-trained | 1 |
| 383 | late-aborting | 1 |
| 384 | lid-control | 1 |
| 385 | lm-485 | 1 |
| 386 | memory/attention-only | 1 |
| 387 | met+cbt | 1 |
| 388 | methanogens-suppressing | 1 |
| 389 | micropost | 1 |
| 390 | msc-only | 1 |
| 391 | n-p-methoxybenzyl | 1 |
| 392 | nadh-bound | 1 |
| 393 | nafld-like | 1 |
| 394 | nnf-treated | 1 |
| 395 | no-prednisone | 1 |
| 396 | non-bipedal | 1 |
| 397 | non-infectiority | 1 |
| 398 | non-ipc | 1 |
| 399 | non-mnps-fe₃o₄-treated | 1 |
| 400 | non-plus-ultra | 1 |
| 401 | nonchemotherapy-treated | 1 |
| 402 | nontherapy | 1 |
| 403 | nonvasculitic | 1 |
| 404 | nonworkshop | 1 |
| 405 | obn | 1 |
| 406 | obvservational | 1 |
| 407 | one-with-many | 1 |
| 408 | one/48 | 1 |
| 409 | one/50 | 1 |
| 410 | otbs | 1 |
| 411 | other-reward | 1 |
| 412 | otomangue | 1 |
| 413 | outbreak-related | 1 |
| 414 | outcall-only | 1 |
| 415 | oxacillin/ceftriaxone | 1 |
| 416 | peak-compression | 1 |
| 417 | perceptual-semantic | 1 |
| 418 | phenotypic-biohumoral | 1 |
| 419 | phz-treated | 1 |
| 420 | pick-klop | 1 |
| 421 | poeciliid | 1 |
| 422 | poisson-based | 1 |
| 423 | randomized-surgeon | 1 |
| 424 | rearing/hygienic | 1 |
| 425 | sb25 | 1 |
| 426 | sb50 | 1 |
| 427 | silibinin-fed | 1 |
| 428 | splicing-disruptive | 1 |
| 429 | sr-containing | 1 |
| 430 | steroid-medicated | 1 |
| 431 | thermoxidative | 1 |
| 432 | thin-peer | 1 |
| 433 | time-intervention | 1 |
| 434 | time-pregnant | 1 |
| 435 | tintinnid | 1 |
| 436 | two-polymerisation | 1 |
| 437 | years.pooled | 1 |
| 1 | 'close-out | 1 |
| 2 | 'existential | 1 |
| 3 | 'exposed | 2 |
| 4 | +avn-abl | 4 |
| 5 | -acupuncture | 1 |
| 6 | 1,600/800-mg | 9 |
| 7 | 1-g/d | 5 |
| 8 | 1-st | 7 |
| 9 | 1.25-mg/ml | 2 |
| 10 | 10,000-lux | 2 |
| 11 | 1800-mg | 5 |
| 12 | 2-acyl | 1 |
| 13 | 3-np+krg | 3 |
| 14 | 3-rd | 4 |
| 15 | 4-night | 2 |
| 16 | 400/400-mg | 6 |
| 17 | 5-set | 5 |
| 18 | 6-hydroxydopamine-lesion | 1 |
| 19 | 6.0-mg/d | 2 |
| 20 | 80-day | 9 |
| 21 | a+-icd | 7 |
| 22 | a-b-a-c-a-bc-a | 1 |
| 23 | abamectin/derquantel | 2 |
| 24 | abstinence-plus-condom | 4 |
| 25 | access-only | 1 |
| 26 | acga | 6 |
| 27 | acprt | 5 |
| 28 | across-intervention | 1 |
| 29 | actg5202 | 2 |
| 30 | active-active | 2 |
| 31 | active-supplementing | 3 |
| 32 | active-treatment | 65 |
| 33 | acupoint-shallow-puncturing | 4 |
| 34 | acupuncture-massage | 3 |
| 35 | acupuncture-medication | 8 |
| 36 | acupuncture-moxibustion-medication | 4 |
| 37 | acupuncture-rehabilitation | 9 |
| 38 | acwl | 4 |
| 39 | ad/ttr+/+ | 2 |
| 40 | adherence-counseling | 1 |
| 41 | adult-learning | 5 |
| 42 | aerobic-training | 5 |
| 43 | after-implementation | 1 |
| 44 | agre | 2 |
| 45 | agsb-repressed | 2 |
| 46 | air-staging | 3 |
| 47 | albumin-treated | 2 |
| 48 | alcohol-type | 1 |
| 49 | all-cellulose | 2 |
| 50 | all-on-4 | 7 |
| 51 | almi | 11 |
| 52 | alteplase-treated | 2 |
| 53 | alternating-sequence | 4 |
| 54 | alternatives.the | 1 |
| 55 | ambient-acclimated | 3 |
| 56 | amsa-guided | 4 |
| 57 | anger-prime | 1 |
| 58 | ankle-brace | 1 |
| 59 | anti-muscarinic-alone | 2 |
| 60 | anti-sanitary | 1 |
| 61 | ap-training | 1 |
| 62 | aplocheiloid | 1 |
| 63 | ar-trained | 1 |
| 64 | arenesulfinyl | 1 |
| 65 | arginine-supplemented | 9 |
| 66 | arterivirus | 4 |
| 67 | articaine-fentanyl | 1 |
| 68 | arts-based | 3 |
| 69 | ascorbate-deficient | 2 |
| 70 | asdas-high | 4 |
| 71 | aspca | 1 |
| 72 | assess/advise/treat | 4 |
| 73 | assistant-push | 7 |
| 74 | at/imt | 3 |
| 75 | at/sham | 3 |
| 76 | attention-control | 59 |
| 77 | attentionally-constrained | 1 |
| 78 | balanced-placebo | 1 |
| 79 | balint | 12 |
| 80 | banerji | 3 |
| 81 | before-freezing | 2 |
| 82 | bevacizumab-throughout | 4 |
| 83 | bf+ssc | 4 |
| 84 | bicavo-bipulmonary | 2 |
| 85 | box-trained | 6 |
| 86 | break-out | 3 |
| 87 | breakout | 18 |
| 88 | bv-supplemented | 1 |
| 89 | cab-za | 6 |
| 90 | capio | 5 |
| 91 | cav2-cpi2 | 3 |
| 92 | cd+n-3pufas | 3 |
| 93 | ceramic-polyethylene | 5 |
| 94 | cgprgps | 2 |
| 95 | cha-cha | 7 |
| 96 | change.the | 2 |
| 97 | chronically-instrumented | 1 |
| 98 | classroom-centered | 4 |
| 99 | clinical/statistical | 1 |
| 100 | cnep | 13 |
| 101 | cobi/ftc/tdf | 1 |
| 102 | cobraplus | 3 |
| 103 | collision-free | 1 |
| 104 | combined-dose | 3 |
| 105 | comparison-group | 3 |
| 106 | comparisons.combined | 1 |
| 107 | conduit+nt-3+nscs | 2 |
| 108 | cough-assisted | 1 |
| 109 | cows/dose | 1 |
| 110 | cyper | 1 |
| 111 | d5w-la | 4 |
| 112 | dad-treated | 3 |
| 113 | dbcare® | 2 |
| 114 | deep-diving | 1 |
| 115 | degarelix-ef | 2 |
| 116 | degraded-speech | 2 |
| 117 | dexketoprophen | 4 |
| 118 | diet+idet | 2 |
| 119 | diet-treatment | 1 |
| 120 | diet-type | 2 |
| 121 | diphtheria.our | 1 |
| 122 | dkc-50 | 3 |
| 123 | dobutamine-treated | 3 |
| 124 | dopamine/dobutamine | 4 |
| 125 | dose-increase | 5 |
| 126 | dose-prediction | 1 |
| 127 | drmpa200z | 6 |
| 128 | drug-only | 4 |
| 129 | dual-night | 3 |
| 130 | ea-pa | 5 |
| 131 | eae-mcherry | 2 |
| 132 | early-discharge | 6 |
| 133 | early-fit | 2 |
| 134 | early-interventional | 1 |
| 135 | early-start | 22 |
| 136 | egcg-treated | 6 |
| 137 | eight-subject | 2 |
| 138 | emf-exposed | 3 |
| 139 | emotion-induction | 1 |
| 140 | endophenotype-based | 1 |
| 141 | endpoint-driven | 1 |
| 142 | enhanced-support | 5 |
| 143 | equivalence/crossover | 1 |
| 144 | es-treated | 2 |
| 145 | esfet | 7 |
| 146 | eth-oxy-carbonyl | 4 |
| 147 | ethanol-injury | 1 |
| 148 | ethnospecific | 1 |
| 149 | ethoxycarbonyloxyethyl | 1 |
| 150 | eutocia | 1 |
| 151 | evening-dose | 7 |
| 152 | event-sampling | 1 |
| 153 | exercise-intervention | 4 |
| 154 | exercise-nmes | 2 |
| 155 | exercise-only | 21 |
| 156 | expectancy-enhancing | 3 |
| 157 | experimental | 20,156 |
| 158 | experimental-comparison | 1 |
| 159 | faster-paced | 2 |
| 160 | fda-required | 2 |
| 161 | febuxostat-treated | 3 |
| 162 | feno-guided | 3 |
| 163 | film-treated | 1 |
| 164 | fio2-guided | 1 |
| 165 | firocoxib-treated | 2 |
| 166 | fit-only | 2 |
| 167 | fittslog | 7 |
| 168 | flu-only | 5 |
| 169 | fluoxetine-containing | 1 |
| 170 | fmud+am | 3 |
| 171 | free-agent | 3 |
| 172 | free-viewing | 4 |
| 173 | frpp-treated | 3 |
| 174 | fructose-supplemented | 4 |
| 175 | ge-tpn | 3 |
| 176 | gemp | 4 |
| 177 | glucose-placebo | 1 |
| 178 | gole | 6 |
| 179 | heated-patch | 1 |
| 180 | heliox® | 5 |
| 181 | high-biomarker | 5 |
| 182 | high-h2 | 5 |
| 183 | high-nutrient | 7 |
| 184 | high-rope | 4 |
| 185 | high-upa/pai-1 | 2 |
| 186 | high-variability | 6 |
| 187 | higher-calorie | 7 |
| 188 | higher-target | 4 |
| 189 | hip-as | 6 |
| 190 | hipfit | 2 |
| 191 | hiv-intervention | 1 |
| 192 | homeotherm | 2 |
| 193 | hupa‑treated | 2 |
| 194 | hyperoxia-preconditioned | 4 |
| 195 | hypertrophy-intensity | 1 |
| 196 | i3c-treated | 4 |
| 197 | ic+ccrt | 6 |
| 198 | ic+rt | 5 |
| 199 | ics-exposed | 1 |
| 200 | id-vaccine | 3 |
| 201 | ilbt | 8 |
| 202 | ilc+c-turp | 1 |
| 203 | ill-explained | 1 |
| 204 | immediate-start | 8 |
| 205 | immediate-treatment | 6 |
| 206 | immersion-time | 2 |
| 207 | immunized/vehicle | 1 |
| 208 | implementation-intention | 4 |
| 209 | importantclinical | 1 |
| 210 | inaddition | 1 |
| 211 | incomplete-double | 1 |
| 212 | inf-mtx | 6 |
| 213 | infarct/no-training | 2 |
| 214 | infarct/training | 2 |
| 215 | instruction-only | 2 |
| 216 | instructor-encouraged | 1 |
| 217 | insulin-increasing | 8 |
| 218 | insulin-metformin | 3 |
| 219 | insulin-provision | 9 |
| 220 | insulin-sensitization | 10 |
| 221 | intensive-treatment | 8 |
| 222 | intent-to-train | 1 |
| 223 | intentional-based | 1 |
| 224 | inter-trialist | 1 |
| 225 | intra-erspc | 1 |
| 226 | intra-polymerase | 2 |
| 227 | ip-ssa | 7 |
| 228 | irs-v | 1 |
| 229 | isaac-ii | 2 |
| 230 | itsi | 8 |
| 231 | ivb+trp | 5 |
| 232 | ivpca-cryo | 1 |
| 233 | jian‑pi‑treated | 5 |
| 234 | laboratory/microbiological | 1 |
| 235 | lai-dose | 1 |
| 236 | language-trained | 1 |
| 237 | late-aborting | 1 |
| 238 | lateral-pin | 3 |
| 239 | ld+deb | 4 |
| 240 | li+ris/valproate | 4 |
| 241 | lid-control | 1 |
| 242 | lidar | 4 |
| 243 | lm-485 | 1 |
| 244 | low-protein-diet | 2 |
| 245 | low-score | 8 |
| 246 | low-variability | 5 |
| 247 | lumacaftor-ivacaftor | 5 |
| 248 | lwt | 6 |
| 249 | magnesium-supplemented | 2 |
| 250 | mcfa-supplemented | 2 |
| 251 | mcpt4-deficient | 3 |
| 252 | memoral | 7 |
| 253 | memory/attention-only | 1 |
| 254 | meric | 6 |
| 255 | meso-phenyl | 2 |
| 256 | met+cbt | 1 |
| 257 | methanogens-suppressing | 1 |
| 258 | mg-sufficient | 2 |
| 259 | micropost | 1 |
| 260 | midazolam-treated | 3 |
| 261 | middling-onset | 2 |
| 262 | migraines/headache | 2 |
| 263 | mlpii-treated | 2 |
| 264 | morning-type | 2 |
| 265 | mpa100z | 5 |
| 266 | mr-fv | 7 |
| 267 | msc-only | 1 |
| 268 | mtf+nac | 3 |
| 269 | muscomorph | 2 |
| 270 | n-bppv | 4 |
| 271 | n-p-methoxybenzyl | 1 |
| 272 | nadh-bound | 1 |
| 273 | nafld-like | 1 |
| 274 | nasal-18 | 7 |
| 275 | nbo6 | 2 |
| 276 | neusidl | 7 |
| 277 | nhl-type | 3 |
| 278 | nipc | 8 |
| 279 | nnf-treated | 1 |
| 280 | no-bicarbonate | 2 |
| 281 | no-breakfast | 5 |
| 282 | no-choice | 10 |
| 283 | no-counting | 4 |
| 284 | no-cue | 2 |
| 285 | no-heparin | 4 |
| 286 | no-incentive | 9 |
| 287 | no-lymphadenectomy | 7 |
| 288 | no-mouthpiece | 3 |
| 289 | no-prednisone | 1 |
| 290 | no-sequence | 3 |
| 291 | non-bevacizumab | 5 |
| 292 | non-bipedal | 1 |
| 293 | non-breathing | 3 |
| 294 | non-colitis | 3 |
| 295 | non-counselling | 4 |
| 296 | non-glazed | 3 |
| 297 | non-hrt | 8 |
| 298 | non-infectiority | 1 |
| 299 | non-ipc | 1 |
| 300 | non-mnps-fe₃o₄-treated | 1 |
| 301 | non-navigation | 4 |
| 302 | non-p | 6 |
| 303 | non-plus-ultra | 1 |
| 304 | non-po | 6 |
| 305 | non-probiotics | 5 |
| 306 | non-purged | 16 |
| 307 | non-saard | 4 |
| 308 | non-tbhq | 3 |
| 309 | non-tzd | 11 |
| 310 | non-video | 5 |
| 311 | non-walking | 3 |
| 312 | nonchemotherapy-treated | 1 |
| 313 | nonextended | 8 |
| 314 | nonincentive | 4 |
| 315 | noninjection | 10 |
| 316 | nonprophylactic | 4 |
| 317 | nonpurpuric | 3 |
| 318 | nonshunt | 5 |
| 319 | nontherapy | 1 |
| 320 | nonvasculitic | 1 |
| 321 | nonworkshop | 1 |
| 322 | norepinephine | 2 |
| 323 | nsaid-muscovite | 5 |
| 324 | nttrap | 4 |
| 325 | o-acetyl | 4 |
| 326 | o-carboxylate | 3 |
| 327 | obn | 1 |
| 328 | obvservational | 1 |
| 329 | octreotide-lar | 7 |
| 330 | ologen | 21 |
| 331 | on-stimulation | 9 |
| 332 | one-vegetable | 3 |
| 333 | one-with-many | 1 |
| 334 | one/48 | 1 |
| 335 | one/50 | 1 |
| 336 | open-enrollment | 6 |
| 337 | ophthalmologist-based | 5 |
| 338 | ortho-dihydroxyl | 2 |
| 339 | os-extended | 2 |
| 340 | otbs | 1 |
| 341 | other-reward | 1 |
| 342 | otomangue | 1 |
| 343 | outbreak-related | 1 |
| 344 | outcall-only | 1 |
| 345 | ovariectomized-hysterectomized | 2 |
| 346 | oxacillin/ceftriaxone | 1 |
| 347 | oxazolone-induced | 3 |
| 348 | oxcar | 3 |
| 349 | package-atmosphere | 3 |
| 350 | partin | 6 |
| 351 | peak-compression | 1 |
| 352 | peer-assessment | 4 |
| 353 | peg-only | 15 |
| 354 | perceptual-semantic | 1 |
| 355 | phenotypic-biohumoral | 1 |
| 356 | physician's-choice | 6 |
| 357 | phytosterol-containing | 4 |
| 358 | phz-treated | 1 |
| 359 | pick-klop | 1 |
| 360 | picture-associated | 3 |
| 361 | pirazolac | 8 |
| 362 | pka-bis | 7 |
| 363 | placebo-minus | 2 |
| 364 | plc-cbt | 4 |
| 365 | pleasant-neutral | 2 |
| 366 | poeciliid | 1 |
| 367 | poisson-based | 1 |
| 368 | polemical | 2 |
| 369 | porocoat | 3 |
| 370 | post-ep | 8 |
| 371 | pre-agent | 3 |
| 372 | pro-self | 35 |
| 373 | ragb-treated | 4 |
| 374 | randomized-surgeon | 1 |
| 375 | rapid-advancement | 2 |
| 376 | rapid-test | 4 |
| 377 | rearing/hygienic | 1 |
| 378 | resistance-load | 2 |
| 379 | rhg-csf-priming | 3 |
| 380 | ridge-preservation | 8 |
| 381 | rme/tpa/ec | 3 |
| 382 | rose-k | 8 |
| 383 | rotation/oscillation | 4 |
| 384 | rt-alone | 3 |
| 385 | rt-only | 7 |
| 386 | saf100 | 2 |
| 387 | salt/tetracycline | 2 |
| 388 | sb25 | 1 |
| 389 | sb50 | 1 |
| 390 | se-deficient | 28 |
| 391 | se-supplemented | 5 |
| 392 | second-cohort | 2 |
| 393 | sham-acupressure | 3 |
| 394 | show-me-synch | 5 |
| 395 | silibinin-fed | 1 |
| 396 | simvastatin-ezetimibe | 12 |
| 397 | single-consent | 2 |
| 398 | single-cutoff | 2 |
| 399 | skills-training | 4 |
| 400 | sling-constraint | 2 |
| 401 | sodar | 6 |
| 402 | soht | 6 |
| 403 | spleen-asthenia | 2 |
| 404 | splicing-disruptive | 1 |
| 405 | sr-containing | 1 |
| 406 | steroid-maintenance | 6 |
| 407 | steroid-medicated | 1 |
| 408 | stratified-randomized | 2 |
| 409 | t12pr | 4 |
| 410 | tdf+emtricitabine | 2 |
| 411 | teleophthalmologic | 10 |
| 412 | thermal-treated | 3 |
| 413 | thermotolerance-inducing | 3 |
| 414 | thermoxidative | 1 |
| 415 | thin-peer | 1 |
| 416 | time-intervention | 1 |
| 417 | time-pregnant | 1 |
| 418 | tintinnid | 1 |
| 419 | tj114-treated | 6 |
| 420 | tolterodine-treated | 3 |
| 421 | top/nic | 7 |
| 422 | tourniquet-up | 2 |
| 423 | tpn-soy | 4 |
| 424 | traditional-approach | 2 |
| 425 | training-plus-screening | 2 |
| 426 | two-polymerisation | 1 |
| 427 | txa-treated | 5 |
| 428 | undrained | 10 |
| 429 | unexpanded | 8 |
| 430 | uroacitides+np | 3 |
| 431 | us+mb-treated | 2 |
| 432 | usual-treatment | 5 |
| 433 | variable-attender | 3 |
| 434 | vnr/cddp | 7 |
| 435 | wide-open | 3 |
| 436 | years.pooled | 1 |
| 437 | α1-3 | 3 |
| 1 | ad/ttr+/+ | 2 |
| 2 | saf100 | 2 |
| 3 | dkc-50 | 3 |
| 4 | one/50 | 1 |
| 5 | sb50 | 1 |
| 6 | high-upa/pai-1 | 2 |
| 7 | actg5202 | 2 |
| 8 | high-h2 | 5 |
| 9 | cav2-cpi2 | 3 |
| 10 | α1-3 | 3 |
| 11 | all-on-4 | 7 |
| 12 | sb25 | 1 |
| 13 | lm-485 | 1 |
| 14 | nbo6 | 2 |
| 15 | nasal-18 | 7 |
| 16 | one/48 | 1 |
| 17 | a-b-a-c-a-bc-a | 1 |
| 18 | aspca | 1 |
| 19 | acga | 6 |
| 20 | cha-cha | 7 |
| 21 | eutocia | 1 |
| 22 | spleen-asthenia | 2 |
| 23 | d5w-la | 4 |
| 24 | ea-pa | 5 |
| 25 | non-plus-ultra | 1 |
| 26 | ip-ssa | 7 |
| 27 | cab-za | 6 |
| 28 | non-bevacizumab | 5 |
| 29 | ld+deb | 4 |
| 30 | pirazolac | 8 |
| 31 | mtf+nac | 3 |
| 32 | rme/tpa/ec | 3 |
| 33 | ethnospecific | 1 |
| 34 | teleophthalmologic | 10 |
| 35 | top/nic | 7 |
| 36 | rearing/hygienic | 1 |
| 37 | meric | 6 |
| 38 | nonpurpuric | 3 |
| 39 | nonprophylactic | 4 |
| 40 | nonvasculitic | 1 |
| 41 | perceptual-semantic | 1 |
| 42 | non-ipc | 1 |
| 43 | nipc | 8 |
| 44 | intra-erspc | 1 |
| 45 | bf+ssc | 4 |
| 46 | 1-g/d | 5 |
| 47 | 6.0-mg/d | 2 |
| 48 | resistance-load | 2 |
| 49 | a+-icd | 7 |
| 50 | faster-paced | 2 |
| 51 | oxazolone-induced | 3 |
| 52 | fio2-guided | 1 |
| 53 | amsa-guided | 4 |
| 54 | feno-guided | 3 |
| 55 | unexpanded | 8 |
| 56 | os-extended | 2 |
| 57 | nonextended | 8 |
| 58 | silibinin-fed | 1 |
| 59 | instructor-encouraged | 1 |
| 60 | non-purged | 16 |
| 61 | years.pooled | 1 |
| 62 | ill-explained | 1 |
| 63 | undrained | 10 |
| 64 | language-trained | 1 |
| 65 | ar-trained | 1 |
| 66 | box-trained | 6 |
| 67 | attentionally-constrained | 1 |
| 68 | comparisons.combined | 1 |
| 69 | hyperoxia-preconditioned | 4 |
| 70 | classroom-centered | 4 |
| 71 | fda-required | 2 |
| 72 | endophenotype-based | 1 |
| 73 | intentional-based | 1 |
| 74 | poisson-based | 1 |
| 75 | arts-based | 3 |
| 76 | ophthalmologist-based | 5 |
| 77 | 'exposed | 2 |
| 78 | emf-exposed | 3 |
| 79 | ics-exposed | 1 |
| 80 | agsb-repressed | 2 |
| 81 | steroid-medicated | 1 |
| 82 | tj114-treated | 6 |
| 83 | txa-treated | 5 |
| 84 | ragb-treated | 4 |
| 85 | firocoxib-treated | 2 |
| 86 | us+mb-treated | 2 |
| 87 | i3c-treated | 4 |
| 88 | dad-treated | 3 |
| 89 | tolterodine-treated | 3 |
| 90 | dobutamine-treated | 3 |
| 91 | alteplase-treated | 2 |
| 92 | nnf-treated | 1 |
| 93 | egcg-treated | 6 |
| 94 | mlpii-treated | 2 |
| 95 | thermal-treated | 3 |
| 96 | midazolam-treated | 3 |
| 97 | film-treated | 1 |
| 98 | albumin-treated | 2 |
| 99 | frpp-treated | 3 |
| 100 | es-treated | 2 |
| 101 | febuxostat-treated | 3 |
| 102 | nonchemotherapy-treated | 1 |
| 103 | phz-treated | 1 |
| 104 | non-mnps-fe₃o₄-treated | 1 |
| 105 | hupa‑treated | 2 |
| 106 | jian‑pi‑treated | 5 |
| 107 | picture-associated | 3 |
| 108 | outbreak-related | 1 |
| 109 | ambient-acclimated | 3 |
| 110 | mcfa-supplemented | 2 |
| 111 | arginine-supplemented | 9 |
| 112 | se-supplemented | 5 |
| 113 | fructose-supplemented | 4 |
| 114 | magnesium-supplemented | 2 |
| 115 | bv-supplemented | 1 |
| 116 | chronically-instrumented | 1 |
| 117 | cough-assisted | 1 |
| 118 | non-glazed | 3 |
| 119 | stratified-randomized | 2 |
| 120 | ovariectomized-hysterectomized | 2 |
| 121 | poeciliid | 1 |
| 122 | tintinnid | 1 |
| 123 | aplocheiloid | 1 |
| 124 | nadh-bound | 1 |
| 125 | 3-rd | 4 |
| 126 | non-saard | 4 |
| 127 | other-reward | 1 |
| 128 | non-tzd | 11 |
| 129 | simvastatin-ezetimibe | 12 |
| 130 | ankle-brace | 1 |
| 131 | no-mouthpiece | 3 |
| 132 | no-choice | 10 |
| 133 | physician's-choice | 6 |
| 134 | steroid-maintenance | 6 |
| 135 | alternating-sequence | 4 |
| 136 | no-sequence | 3 |
| 137 | collision-free | 1 |
| 138 | acupuncture-massage | 3 |
| 139 | early-discharge | 6 |
| 140 | migraines/headache | 2 |
| 141 | change.the | 2 |
| 142 | alternatives.the | 1 |
| 143 | higher-calorie | 7 |
| 144 | nafld-like | 1 |
| 145 | one-vegetable | 3 |
| 146 | incomplete-double | 1 |
| 147 | immunized/vehicle | 1 |
| 148 | gole | 6 |
| 149 | anger-prime | 1 |
| 150 | immersion-time | 2 |
| 151 | ceramic-polyethylene | 5 |
| 152 | tdf+emtricitabine | 2 |
| 153 | id-vaccine | 3 |
| 154 | norepinephine | 2 |
| 155 | salt/tetracycline | 2 |
| 156 | dopamine/dobutamine | 4 |
| 157 | anti-muscarinic-alone | 2 |
| 158 | rt-alone | 3 |
| 159 | no-prednisone | 1 |
| 160 | oxacillin/ceftriaxone | 1 |
| 161 | high-rope | 4 |
| 162 | morning-type | 2 |
| 163 | nhl-type | 3 |
| 164 | alcohol-type | 1 |
| 165 | diet-type | 2 |
| 166 | package-atmosphere | 3 |
| 167 | agre | 2 |
| 168 | low-score | 8 |
| 169 | sham-acupressure | 3 |
| 170 | -acupuncture | 1 |
| 171 | dose-increase | 5 |
| 172 | intra-polymerase | 2 |
| 173 | combined-dose | 3 |
| 174 | evening-dose | 7 |
| 175 | lai-dose | 1 |
| 176 | cows/dose | 1 |
| 177 | all-cellulose | 2 |
| 178 | o-carboxylate | 3 |
| 179 | no-bicarbonate | 2 |
| 180 | li+ris/valproate | 4 |
| 181 | nsaid-muscovite | 5 |
| 182 | no-cue | 2 |
| 183 | otomangue | 1 |
| 184 | thermoxidative | 1 |
| 185 | active-active | 2 |
| 186 | no-incentive | 9 |
| 187 | nonincentive | 4 |
| 188 | splicing-disruptive | 1 |
| 189 | cobi/ftc/tdf | 1 |
| 190 | degarelix-ef | 2 |
| 191 | single-cutoff | 2 |
| 192 | pro-self | 35 |
| 193 | 400/400-mg | 6 |
| 194 | 1,600/800-mg | 9 |
| 195 | 1800-mg | 5 |
| 196 | expectancy-enhancing | 3 |
| 197 | thermotolerance-inducing | 3 |
| 198 | air-staging | 3 |
| 199 | non-breathing | 3 |
| 200 | non-walking | 3 |
| 201 | adherence-counseling | 1 |
| 202 | non-counselling | 4 |
| 203 | event-sampling | 1 |
| 204 | rhg-csf-priming | 3 |
| 205 | training-plus-screening | 2 |
| 206 | aerobic-training | 5 |
| 207 | infarct/no-training | 2 |
| 208 | ap-training | 1 |
| 209 | skills-training | 4 |
| 210 | infarct/training | 2 |
| 211 | fluoxetine-containing | 1 |
| 212 | phytosterol-containing | 4 |
| 213 | sr-containing | 1 |
| 214 | adult-learning | 5 |
| 215 | acupoint-shallow-puncturing | 4 |
| 216 | insulin-increasing | 8 |
| 217 | methanogens-suppressing | 1 |
| 218 | active-supplementing | 3 |
| 219 | no-counting | 4 |
| 220 | late-aborting | 1 |
| 221 | deep-diving | 1 |
| 222 | free-viewing | 4 |
| 223 | before-freezing | 2 |
| 224 | fittslog | 7 |
| 225 | 3-np+krg | 3 |
| 226 | traditional-approach | 2 |
| 227 | degraded-speech | 2 |
| 228 | show-me-synch | 5 |
| 229 | heated-patch | 1 |
| 230 | asdas-high | 4 |
| 231 | muscomorph | 2 |
| 232 | assistant-push | 7 |
| 233 | isaac-ii | 2 |
| 234 | banerji | 3 |
| 235 | almi | 11 |
| 236 | itsi | 8 |
| 237 | rose-k | 8 |
| 238 | laboratory/microbiological | 1 |
| 239 | polemical | 2 |
| 240 | importantclinical | 1 |
| 241 | clinical/statistical | 1 |
| 242 | non-bipedal | 1 |
| 243 | 'existential | 1 |
| 244 | obvservational | 1 |
| 245 | early-interventional | 1 |
| 246 | memoral | 7 |
| 247 | phenotypic-biohumoral | 1 |
| 248 | pleasant-neutral | 2 |
| 249 | experimental | 20,156 |
| 250 | +avn-abl | 4 |
| 251 | neusidl | 7 |
| 252 | abamectin/derquantel | 2 |
| 253 | 1.25-mg/ml | 2 |
| 254 | lid-control | 1 |
| 255 | attention-control | 59 |
| 256 | acwl | 4 |
| 257 | 2-acyl | 1 |
| 258 | ethoxycarbonyloxyethyl | 1 |
| 259 | articaine-fentanyl | 1 |
| 260 | meso-phenyl | 2 |
| 261 | arenesulfinyl | 1 |
| 262 | eth-oxy-carbonyl | 4 |
| 263 | o-acetyl | 4 |
| 264 | ortho-dihydroxyl | 2 |
| 265 | n-p-methoxybenzyl | 1 |
| 266 | fmud+am | 3 |
| 267 | at/sham | 3 |
| 268 | abstinence-plus-condom | 4 |
| 269 | homeotherm | 2 |
| 270 | obn | 1 |
| 271 | ologen | 21 |
| 272 | dexketoprophen | 4 |
| 273 | wide-open | 3 |
| 274 | endpoint-driven | 1 |
| 275 | intent-to-train | 1 |
| 276 | insulin-metformin | 3 |
| 277 | lateral-pin | 3 |
| 278 | no-heparin | 4 |
| 279 | partin | 6 |
| 280 | randomized-surgeon | 1 |
| 281 | 6-hydroxydopamine-lesion | 1 |
| 282 | insulin-provision | 9 |
| 283 | peak-compression | 1 |
| 284 | acupuncture-medication | 8 |
| 285 | acupuncture-moxibustion-medication | 4 |
| 286 | non-navigation | 4 |
| 287 | rotation/oscillation | 4 |
| 288 | on-stimulation | 9 |
| 289 | two-polymerisation | 1 |
| 290 | acupuncture-rehabilitation | 9 |
| 291 | after-implementation | 1 |
| 292 | ridge-preservation | 8 |
| 293 | insulin-sensitization | 10 |
| 294 | noninjection | 10 |
| 295 | dose-prediction | 1 |
| 296 | emotion-induction | 1 |
| 297 | inaddition | 1 |
| 298 | implementation-intention | 4 |
| 299 | time-intervention | 1 |
| 300 | exercise-intervention | 4 |
| 301 | across-intervention | 1 |
| 302 | hiv-intervention | 1 |
| 303 | experimental-comparison | 1 |
| 304 | ge-tpn | 3 |
| 305 | balanced-placebo | 1 |
| 306 | glucose-placebo | 1 |
| 307 | non-video | 5 |
| 308 | capio | 5 |
| 309 | non-po | 6 |
| 310 | ivpca-cryo | 1 |
| 311 | non-p | 6 |
| 312 | nttrap | 4 |
| 313 | vnr/cddp | 7 |
| 314 | post-ep | 8 |
| 315 | cnep | 13 |
| 316 | gemp | 4 |
| 317 | uroacitides+np | 3 |
| 318 | nonworkshop | 1 |
| 319 | pick-klop | 1 |
| 320 | ivb+trp | 5 |
| 321 | ilc+c-turp | 1 |
| 322 | tourniquet-up | 2 |
| 323 | comparison-group | 3 |
| 324 | non-tbhq | 3 |
| 325 | oxcar | 3 |
| 326 | lidar | 4 |
| 327 | sodar | 6 |
| 328 | octreotide-lar | 7 |
| 329 | variable-attender | 3 |
| 330 | thin-peer | 1 |
| 331 | high-biomarker | 5 |
| 332 | cyper | 1 |
| 333 | equivalence/crossover | 1 |
| 334 | lumacaftor-ivacaftor | 5 |
| 335 | t12pr | 4 |
| 336 | diphtheria.our | 1 |
| 337 | hip-as | 6 |
| 338 | cd+n-3pufas | 3 |
| 339 | otbs | 1 |
| 340 | non-probiotics | 5 |
| 341 | conduit+nt-3+nscs | 2 |
| 342 | exercise-nmes | 2 |
| 343 | pka-bis | 7 |
| 344 | non-colitis | 3 |
| 345 | cgprgps | 2 |
| 346 | cobraplus | 3 |
| 347 | placebo-minus | 2 |
| 348 | arterivirus | 4 |
| 349 | assess/advise/treat | 4 |
| 350 | porocoat | 3 |
| 351 | met+cbt | 1 |
| 352 | plc-cbt | 4 |
| 353 | ilbt | 8 |
| 354 | eight-subject | 2 |
| 355 | diet+idet | 2 |
| 356 | esfet | 7 |
| 357 | higher-target | 4 |
| 358 | low-protein-diet | 2 |
| 359 | 5-set | 5 |
| 360 | middling-onset | 2 |
| 361 | 4-night | 2 |
| 362 | dual-night | 3 |
| 363 | soht | 6 |
| 364 | early-fit | 2 |
| 365 | hipfit | 2 |
| 366 | at/imt | 3 |
| 367 | time-pregnant | 1 |
| 368 | free-agent | 3 |
| 369 | pre-agent | 3 |
| 370 | mcpt4-deficient | 3 |
| 371 | se-deficient | 28 |
| 372 | ascorbate-deficient | 2 |
| 373 | mg-sufficient | 2 |
| 374 | high-nutrient | 7 |
| 375 | rapid-advancement | 2 |
| 376 | open-enrollment | 6 |
| 377 | peer-assessment | 4 |
| 378 | immediate-treatment | 6 |
| 379 | intensive-treatment | 8 |
| 380 | active-treatment | 65 |
| 381 | usual-treatment | 5 |
| 382 | diet-treatment | 1 |
| 383 | single-consent | 2 |
| 384 | sling-constraint | 2 |
| 385 | balint | 12 |
| 386 | nonshunt | 5 |
| 387 | ic+rt | 5 |
| 388 | immediate-start | 8 |
| 389 | early-start | 22 |
| 390 | ic+ccrt | 6 |
| 391 | non-hrt | 8 |
| 392 | second-cohort | 2 |
| 393 | enhanced-support | 5 |
| 394 | acprt | 5 |
| 395 | 1-st | 7 |
| 396 | no-breakfast | 5 |
| 397 | rapid-test | 4 |
| 398 | inter-trialist | 1 |
| 399 | micropost | 1 |
| 400 | 'close-out | 1 |
| 401 | break-out | 3 |
| 402 | bevacizumab-throughout | 4 |
| 403 | breakout | 18 |
| 404 | lwt | 6 |
| 405 | irs-v | 1 |
| 406 | mr-fv | 7 |
| 407 | n-bppv | 4 |
| 408 | inf-mtx | 6 |
| 409 | 10,000-lux | 2 |
| 410 | 80-day | 9 |
| 411 | msc-only | 1 |
| 412 | exercise-only | 21 |
| 413 | peg-only | 15 |
| 414 | drug-only | 4 |
| 415 | outcall-only | 1 |
| 416 | instruction-only | 2 |
| 417 | memory/attention-only | 1 |
| 418 | access-only | 1 |
| 419 | fit-only | 2 |
| 420 | rt-only | 7 |
| 421 | flu-only | 5 |
| 422 | no-lymphadenectomy | 7 |
| 423 | one-with-many | 1 |
| 424 | tpn-soy | 4 |
| 425 | nontherapy | 1 |
| 426 | bicavo-bipulmonary | 2 |
| 427 | anti-sanitary | 1 |
| 428 | eae-mcherry | 2 |
| 429 | ethanol-injury | 1 |
| 430 | high-variability | 6 |
| 431 | low-variability | 5 |
| 432 | non-infectiority | 1 |
| 433 | hypertrophy-intensity | 1 |
| 434 | mpa100z | 5 |
| 435 | drmpa200z | 6 |
| 436 | dbcare® | 2 |
| 437 | heliox® | 5 |